Apoptosis and drug response

Current Opinion in Oncology

Volumn 11, Issue 6, 1999, Pages 475-481

  Houghton, Janet A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG RESPONSE; EXPERIMENTAL MODEL; HUMAN; MITOSIS; NECROSIS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; APOPTOSIS; DNA DAMAGE; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0032748746     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199911000-00008     Document Type: Short Survey

References (70)

1. 1 Brown JM, Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1998, 59:1391-1399. This review critically evaluates the role of p53 in the induction of apoptosis following DNA damage and indicates that p53 may influence the threshold and kinetics of apoptosis induction but not overall survival of a treated population.
2. 2 Aldridge DR, Radford IR: Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res 1998, 58:2817-2824.
3. 3 Weller M: Predicting the response to chemotherapy: the role of p53. Cell Tissue Res 1998, 292:435-445.
4. 4 Stahler F, Roemer K; Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wtp53. Oncogene 1998, 17:3507-3512.
5. 5 Burger H, Nooter K, Boersma AW, van Wingerden KE, Looijenga LH, Jochemsen AG, Stoter G: Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999, 81:620-628.
6. 6 Blandino G, Levine AJ, Oren M: Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18:477-485. This study demonstrates that only certain p53 mutants may confer a selective survival advantage for tumor cells following chemotherapy, as determined from assays of apoptosis and clonogenic survival.
7. 7 Tetu B, Brisson J, Plante V, Bernard P: P53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998, 11:823-830.
8. 8 Calvert AH, Ghokul S, Al-Azraqi A, Wright J, Lind M, Bailey N, et al.: Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. Semin Oncol 1999, 26(suppl 2):90-94.
9. 9 Giaccia AJ, Kastan MB: The complexity of p53 modulation: emerging patterns from divergent signals. Gene Dev 1998, 12:2973-2983. This provides a comprehensive review of the diversity of signals that regulate p53 function.
10. 10 Palmero I, Pantoja C, Serrano M: P14ARF links the tumour suppressors RB and p53. Nature 1998, 395:124-126.
11. 11 Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Gene Dev 1998, 12:2984-2991.
12. 12 Canman CE, Lim D-S: The role of ATM in DNA damage responses and cancer. Oncogene 1998, 17:3301-3308.
13. 13 Kharbanda S, Yuan Z-M, Weichselbaum R, Kufe D: Determination of cell fate by c-Abl activation in response4 to DNA damage. Oncogene 1998, 17:3309-3318.
14. 14 Dang CV: C-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999, 19:1-11.
15. 15 Fulda S, Lutz W, Schwab M, Debatin K-M: MycN sensitizes neuroblastoma cells for drug-induced apoptotis. Oncogene 18:1479-1486.
16. 16 Koo HM, Gray-Goodrich M, Kohlhagen G, McWilliams MJ, Jeffers M, Vaigro-Wolff A, et al.: The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J Natl Cancer Inst 1999, 91:236-244.
17. 17 Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol Cell 1998, 1:543-551. This study demonstrates that VP-16-and VM-26-induced, Fas-dependent apoptosis is mediated via direct transcriptional activation of FasL by both NF-κB and AP-1 in Jurkat T leukemia cells.
18. 18 Kasibhatla S, Genestier L, Green DR: Regulation of Fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor κB. J Biol Chem 1999, 274:987-992.
19. 19 Faris M, Latinis KM, Kempiak SJ, Koretzky GA, Nel A: Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter. Mol Cell Biol 1998, 18:5414-5424.
20. 20 Li N, Karin M: Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc Natl Acad Sci U S A 1998, 95:13012-13017.
21. 21 Waddick KG, Uckun FM: Innovative treatment programs against cancer II. Nuclear factor-κB (NF-κB) as a molecular target. Biochem Pharmacol 1999, 57:9-17.
22. 22 Jarvis WD, Grant S: The role of ceramide in the cellular response to cytotoxic agents. Curr Opin Oncol 1998, 10:552-559.
23. 23 Tillman DM, Petak I, Houghton JA: A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999, 5:425-430. This study demonstrates that FUra/LV-induced thymineless death is potentiated by IFN-γ in a Fas-dependent and p53-independent manner in colon carcinoma cells, indicating that Fas may be an important target for therapeutic modulation.
24. 24 Ruiz-Ruiz M del C, Lopez-Rivas A: P53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells. Cell Death Diff 1999, 6:271-280.
25. 25 Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaak JB, Duke RC: Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Diff 1999, 6:175-182.
26. 26 Rokhlin OW, Glover RA, Cohen MB: Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res 1998, 58:5870-5875.
27. 27 Fulda S, Susin SA, Kroemer G, Debatin K-M: Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998, 58:4453-4460.
28. 28 Yount GL, Levine KS, Kuriyama H, Haas-Kogan DA, Israel MA: Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells. Cancer Res 1999, 59:1362-1365.
29. 29 Wagenknecht B, Schulz JB, Gulbins E, Weller M: Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death Diff 1998, 5:894-900.
30. 30 Fulda S, Scaffidi C, Pietsch T, Krammer PH, Peter ME, Debatin K-M: Activation of the CD95 (APO-1/Fas) pathway in drug-and γ-irradiation-induced apoptosis of brain tumor cells. Cell Death Diff 1998, 5:884-893.
31. 31 Kontny HU, Lehrnbecher TM, Chanock SJ, Mackall CL: Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma. Cancer Res 1998, 58:5842-5849.
32. 32 Gutierrez MI, Cherney B, Hussain A, Mostowski H, Tosato G, Magrath I, Bhatia K: Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res 1999, 59:696-703.
33. 33 Posovsky C, Friesen C, Herr I, Debatin K-M: Chemotherapeutic drugs sensitize pre-B ALL cells for CD95-and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia 1999, 13:400-409.
34. 34 Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D'Alessandro N, Papogg G, et al.: The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Diff 1998, 5:735-742.
35. 35 Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, et al.: P53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998, 188:2033-2045.
36. 36 Faris M, Kokot N, Latinis K, Kasibhatla S, Green DR, Koretzky GA, Nel A: The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J Immunol 1998, 160:134-144.
37. 37 Tillman DM, Harwood FG, Gibson AA, Houghton JA: Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells. Cell Death Diff 1998, 5:450-457. This study identifies Fas as the most critical determinant of Fas-dependent cytotoxicity in human colon carcinoma cell lines.
38. 38 Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, et al.: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703.
39. 39 Scaffidi C, Schmilz I, Krammer PH, Peter ME: The role of c-FLIP in modulation of CD-95-induced apoptosis. J Biol Chem 1999, 274:1541-1548. This report identifies c-FLIP as a critical determinant of apoptosis induced via activation of caspase-8 and hence Fas-dependent apoptosis.
40. 40 Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT: Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999, 274:7987-7992.
41. 41 Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K: Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/logand interaction. Blood 1999, 93:3053-3063.
42. 42 Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al.: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675-1687.
43. 43 Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, et al.: Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 1998, 431:351-356.
44. 44 Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashkenazi A: Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol 1998, 8:525-528.
45. 45 Griffith TS, Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin in Immunol 1998, 10:559-563. This provides a comprehensive review of the current status of the function of TRAIL, expression of its receptors, and TRAIL signaling, including data on neoplastic cell lines.
46. 46 Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
47. 47 Frank S, Kohler U, Schackert G, Schackert HK: Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun 1999, 257:454-459.
48. 48 Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998, 161:2833-2840. This study demonstrates that treatment of TRAIL-resisfant melanoma cell lines with actinomycin-D downregulated c-FLIP expression and sensitized cells to TRAIL-induced apoptosis.
49. 49 Thomas WD, Hersey P: TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998, 161:2195-2200.
50. 50 Walczak H, Miller RE, Ariail K, Gilniak B, Griffith TS, Kubin M, et al.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med 1999, 5:157-163.
51. 51 Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M: APO2 ligand: a novel weapon against malignant glioma? FEBS Lett 1998, 124-128.
52. 52 Martinez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapai A, Pineiro A, et al.: Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998, 28:2714-2725.
53. 53 Arai T, Akiyama Y, Okabe S, Saito K, Iwai T, Yuasa Y: Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas. Cancer Lett 1998, 133:197-204.
54. 54 Pai SI, Wu GS, Ozoren N, Wu L, Jen J, Sidransky D, et al.: Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998, 58:3513-3518.
55. 55 Sheikh IS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et al.: P53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumnor necrosis factor α. Cancer Res 1998, 58:1593-1598.
56. 56 Wajant H, Johannes F-J, Haas E, Siemienski K, Schwenzer R, Schubert G, et al.: Dominant-negative FADD inhibits TNFR60-, Fas/Apo1-and TRAIL-R/Apo2-mediated cell death but not gene induction. Curr Biol 1998, 8:113-116.
57. 57 Herr I, Wilhelm D, Meyer E, Jeremias I, Angel P, Debatin K-M: JNK/SAPK activity contributed to TRAIL-induced apoptosis. Cell Death Diff 1999, 6:130-135.
58. 58 Nunez G, Benedict MA, Hu Y, Inohara N: Caspases: the proteases of the apoptotic pathway. Oncogene 1998, 17:3237-3245.
59. 59 Green DR: Apoptotic pathways: the roads to ruin. Cell 1998, 94:695-698.
60. 60 Stroh C, Schulze-Osthoff K: Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Diff 1998, 5:997-1000.
61. 61 Reed JC: Bcl-2 family proteins. Oncogene 1998, 17:3237-3246.
62. 62 Song Q, Kuang Y, Dixit VM, Vincenz C: Boo, a novel negative regulator of cell death, interacts with Apaf-1. EMBO J 1999, 18:167-178.
63. 63 Reed JC: Bcl-2 family proteins: relative importance as determinants of chemoresistance in cancer. In Apoptosis and Cancer Chemotherapy. Edited by Hickman JA, Dive C. Totowa, NJ: Humana Press; 1999:99-116.
64. 64 Amarante-Mendes GP, Finucane DM, Martin SJ, Cotter TG, Salvesen GS, Green DR: Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. Cell Death Diff 1998, 5:298-306. This report indicates that Bcl-2 expression or inhibition of caspase activation by zVAD-fmk-inhibited actinomycin-D-and VP-16-induced apoptosis but not loss in clonogenic survival in Jurkat cells, where cells displayed morphologic signs of necrosis. In contrast the caspase inhibitor prevented Fas-mediated apoptosis and loss in clonogenic survival.
65. 65 Breton C, Story MD, Meyn RE: Bcl-2 expression correlates with apoptosis induction but not loss of cfonogenic survival in small cell lung cancer cell lines treated with etoposide. Anticancer Drugs 1998, 9:751-757.
66. 66 Come MG, Skladanowski A, Larsen AK, Laurent G: Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells. Br J Cancer 1999, 79:1090-1097.
67. 67 Lui WY, Chang YF, Li LL, Ho LK, Su TL, Chen JY, et al.: Differential paclitaxel-induced cytotoxicity in rodent and human hepatoma cell lines. Anticancer Res 1998, 18:3339-3345.
68. 68 Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al.: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
69. 69 Rupnow BA, Murtha AD, Alarcon RM, Giaccia AJ, Knox SJ: Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res 1998, 58:1779-1784.
70. 70 Norgaard JM, Jensen PD, Bendix K, Clausen N, Palshof T: Relevance of in vitro leukaemia cell survival to short-and long-term clinical outcome in AML. Leuk Lymphoma 1999, 32:327-337.